Form 4: Alaunos Therapeutics CEO Acquires Shares
Statement of Changes in Beneficial Ownership
Alaunos Therapeutics CEO Holger Weis acquired 7,761 shares of common stock for $2.26 per share, totaling $17,540.76, as part of a salary payment.
Summary
- Holger Weis, Chief Executive Officer of Alaunos Therapeutics, Inc., acquired 7,761 shares of common stock on June 12, 2026.
- The acquisition was made in lieu of net salary, with each share valued at $2.26.
- Following this transaction, Weis beneficially owns 12,672 shares of common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation-related transaction for an executive rather than a significant strategic or financial event.
Positives
- CEO's continued investment in the company through share acquisition.
- The acquisition was made in lieu of salary, indicating a potential cash preservation strategy for the company.
Future Outlook
No specific future outlook or guidance is provided in this filing.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into executive compensation and ownership. This specific transaction indicates a non-cash compensation arrangement for the CEO.
Stakeholder Impact
- Shareholders: Increased transparency into executive compensation and potential cash flow management by the company.
- Employees: Indirectly impacted by the company's compensation strategies.
- Management: CEO's compensation structure is detailed.
Key Dates
| Date | Description |
|---|---|
| 06/17/2026 | Date of filing of the statement of changes in beneficial ownership. |
| 06/12/2026 | Transaction date for the acquisition of common stock. |
Keywords
Alaunos Therapeutics, TCRT, Form 4, Insider Trading, Executive Compensation, Common Stock, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.